FTC Asks Federal Court to Hold Martin Shkreli in Contempt Over Pharma Ban

Key facts

The Federal Trade Commission (FTC) returned to federal court to seek formal contempt sanctions against Martin Shkreli, alleging that the former biotechnology executive has engaged in actions that directly violate the permanent injunction issued against him. According to reporting by STAT News, regulators urged the court to intervene after determining that Shkreli had engaged in ongoing activities connected to the pharmaceutical domain despite explicit legal prohibitions.

Civil contempt filings in U.S. federal courts serve as a primary enforcement tool when a defendant fails to comply with a binding judicial order or permanent injunction. In antitrust cases, the FTC routinely monitors compliance with court-ordered structural remedies and personal bans to ensure that individuals subjected to industry exclusions do not maintain undisclosed influence, offer advisory services, or operate shadow enterprises within restricted commercial sectors.

The FTC’s motion asks the court to enforce the strict terms established in the original 2022 decree. While the full evidentiary record accompanying the motion outlines specific conduct alleged by regulatory counsel, contempt proceedings generally allow federal judges to impose punitive measures, including escalating daily monetary fines, coercive sanctions, or structural restrictions, until full compliance is demonstrated.

Why it matters

The FTC’s move to hold Shkreli in contempt underscores the rigorous stance federal enforcement agencies are adopting toward corporate misconduct and the enforcement of personal industry bans. Lifetime exclusions from an entire commercial sector are among the most severe remedies available under federal antitrust law. If courts do not aggressively penalize violations of these bans, the deterrent value of structural remedies against executive misconduct across the healthcare and life sciences sectors could be significantly diluted.

For patients, healthcare providers, and commercial buyers of prescription medications, the integrity of federal antitrust remedies directly impacts market access and affordability. When executives employ anti-competitive tactics to delay or block generic alternatives, drug prices remain artificially inflated, placing severe financial burdens on health systems and vulnerable patient populations. Ensuring that individuals convicted of suppressing market competition cannot re-enter the market through advisory positions, venture capital investments, or third-party entities is vital for maintaining competitive pricing in generic drug markets.

Furthermore, this proceeding demonstrates the long-term operational reach of federal regulatory oversight. Winning a permanent injunction in court is only the first phase of regulatory enforcement; sustained monitoring and prompt judicial enforcement are required to guarantee that judicial orders maintain their legal force over decades. The case sets a critical precedent for how federal courts handle repeat regulatory non-compliance in specialized fields like biotechnology and pharmaceuticals.

To understand the legal foundation of the FTC's contempt motion, it is necessary to examine the history of Shkreli’s pharmaceutical activities and the complex antitrust litigation that led to his permanent industry ban.

In 2015, Shkreli was the chief executive officer of Turing Pharmaceuticals (which later rebranded as Vyera Pharmaceuticals). In August of that year, Turing acquired the exclusive U.S. rights to Daraprim (pyrimethamine), a 62-year-old medication recognized by the World Health Organization as an essential treatment for toxoplasmosis. Toxoplasmosis is a parasitic infection that can cause severe, life-threatening complications in individuals with compromised immune systems, including HIV/AIDS patients, cancer patients undergoing chemotherapy, and organ transplant recipients.

Immediately after securing control of Daraprim, Turing raised the price of the drug overnight from $13.50 per tablet to $750 per tablet—an increase of approximately 5,450 percent. Because Daraprim had long been out of patent protection, generic manufacturers theoretically could have produced cheaper alternatives. However, Turing executed a deliberate strategy to prevent generic competitors from entering the market.

Under Shkreli's direction, Turing restricted distribution of Daraprim through specialized closed networks, preventing generic drug manufacturers from obtaining the physical samples of the medication required by the U.S. Food and Drug Administration (FDA) to perform bioequivalence testing. In addition, the company entered into exclusive supply agreements with the primary global suppliers of the active pharmaceutical ingredient (API) needed to manufacture pyrimethamine, effectively locking potential rivals out of the supply chain.

In January 2020, the FTC and seven states—New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia—filed a comprehensive civil antitrust lawsuit against Shkreli, Vyera Pharmaceuticals, and business partner Kevin Mulleady in the U.S. District Court for the Southern District of New York. The lawsuit charged the defendants with executing an illegal scheme to monopolize the market for pyrimethamine and suppress generic competition.

Following a bench trial in late 2021, U.S. District Judge Denise Cote issued a sweeping decision in January 2022. Judge Cote found Shkreli liable for federal and state antitrust violations, describing his conduct as egregious and deliberate. The court issued an injunction permanently banning Shkreli from participating in the pharmaceutical industry in any capacity, including serving as an officer, director, consultant, or agent for any pharmaceutical company, or acquiring an ownership interest in such entities beyond passive public stock investments. Judge Cote also ordered Shkreli to pay $64.6 million in disgorgement to refund illegal profits.

Shkreli appealed the ruling, arguing that a lifetime industry ban was overly broad and unconstitutional. In February 2024, a three-judge panel of the U.S. Court of Appeals for the Second Circuit unanimously rejected his appeal, upholding both the lifetime ban and the $64.6 million monetary order. Parallel to these civil antitrust proceedings, Shkreli served a federal prison sentence after being convicted in 2017 of three counts of securities fraud related to his management of hedge funds MSMB Capital Management and MSMB Healthcare, as well as biopharmaceutical company Retrophin. He was released from federal custody in May 2022.

Reaction

Regulatory officials have maintained a firm position regarding compliance with federal court mandates. The FTC and state attorneys general involved in the original litigation have repeatedly stated that enforcement of the 2022 injunction is essential to protecting consumers from anti-competitive drug pricing practices. New York Attorney General Letitia James, who co-led the state coalition against Shkreli, previously characterized the original court ruling as a historic victory against price gouging and corporate greed.

Shkreli and his legal representatives are expected to contest the FTC's contempt petition in federal court. In past proceedings, Shkreli's defense team has argued that his public statements, online commentaries, and technical projects do not constitute formal employment or commercial operations within the pharmaceutical sector prohibited by the injunction.

Consumer advocacy groups, public health organizations, and antitrust experts are closely monitoring the court’s response. Industry observers anticipate that public health organizations will welcome the FTC’s swift intervention, viewing it as a necessary enforcement of legal boundaries set to preserve fair competition in the prescription drug market.

What we don't know yet

Several operational and legal details remain unconfirmed in the immediate aftermath of the FTC's filing:

What to watch

Moving forward, key developments will determine the outcome of this legal conflict:

This report incorporates information originally reported by STAT News journalist Ed Silverman.